Targeting Divergent Pathways in the Nutritional Management of Depression

Overview

Journal Nutrients

Date 2024 Aug 29

PMID 39203943

Authors

Derek Tobin

Alexander Vuckovic

Jerome Sarris

Affiliations

Soon will be listed here.

Abstract

The nutritional management of depression has long been discussed, due to the perceived benefit of a nutritional product having less side effects than pharmaceutical agents. Candidate nutrients for managing depression include vitamin D, B vitamins, tryptophan, branch chain amino acids, probiotics, omega-3 fatty acids, folate/methylfolate (also known as vitamin B9), and s-adenosylmethionine. This paper provides a narrative review of three nutrients which have significant scientific support for the management of depression. A deficiency in each nutrient is associated with depression, and interventional studies indicate that the correction of the nutritional deficiency may provide clinical benefit. We present epidemiological evidence, a mechanistic explanation and a review of interventional studies for these nutrients. Finally, relevant nutritional guidelines are presented with their conclusion for the role of each nutrient in the management of depression.

References

Saccarello A, Montarsolo P, Massardo I, Picciotto R, Pedemonte A, Castagnaro R . Oral Administration of S-Adenosylmethionine (SAMe) and Lactobacillus Plantarum HEAL9 Improves the Mild-To-Moderate Symptoms of Depression: A Randomized, Double-Blind, Placebo-Controlled Study. Prim Care Companion CNS Disord. 2020; 22(4). DOI: 10.4088/PCC.19m02578. View

Watanabe N, Matsuoka Y, Kumachi M, Hamazaki K, Horikoshi M, Furukawa T . Omega-3 fatty acids for a better mental state in working populations - Happy Nurse Project: A 52-week randomized controlled trial. J Psychiatr Res. 2018; 102:72-80. DOI: 10.1016/j.jpsychires.2018.03.015. View

Smith D, Sarris J, Dowling N, OConnor M, Ng C . Adjunctive low-dose docosahexaenoic acid (DHA) for major depression: An open-label pilot trial. Nutr Neurosci. 2017; 21(3):224-228. DOI: 10.1080/1028415X.2017.1283128. View

Howland R . Dietary supplement drug therapies for depression. J Psychosoc Nurs Ment Health Serv. 2012; 50(6):13-6. DOI: 10.3928/02793695-20120508-06. View

Liwinski T, Lang U . Folate and Its Significance in Depressive Disorders and Suicidality: A Comprehensive Narrative Review. Nutrients. 2023; 15(17). PMC: 10490031. DOI: 10.3390/nu15173859. View

Whiteford H, Degenhardt L, Rehm J, Baxter A, Ferrari A, Erskine H . Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet. 2013; 382(9904):1575-86. DOI: 10.1016/S0140-6736(13)61611-6. View

Ramos M, Allen L, Haan M, Green R, Miller J . Plasma folate concentrations are associated with depressive symptoms in elderly Latina women despite folic acid fortification. Am J Clin Nutr. 2004; 80(4):1024-8. DOI: 10.1093/ajcn/80.4.1024. View

Kalman D, Feldman S, Vazquez R, Krieger D . A Prospective Randomized Double-Blind Study Evaluating UP165 and -Adenosyl-l-Methionine on Depression, Anxiety and Psychological Well-Being. Foods. 2017; 4(2):130-139. PMC: 5302331. DOI: 10.3390/foods4020130. View

Targum S, Cameron B, Ferreira L, MacDonald I . An augmentation study of MSI-195 (S-adenosylmethionine) in Major Depressive Disorder. J Psychiatr Res. 2018; 107:86-96. DOI: 10.1016/j.jpsychires.2018.10.010. View

10.

Stahl S . Novel therapeutics for depression: L-methylfolate as a trimonoamine modulator and antidepressant-augmenting agent. CNS Spectr. 2007; 12(10):739-44. DOI: 10.1017/s1092852900015418. View

11.

Rush A . STAR*D: what have we learned?. Am J Psychiatry. 2007; 164(2):201-4. DOI: 10.1176/ajp.2007.164.2.201. View

12.

Chiaie R, Pancheri P, Scapicchio P . Efficacy and tolerability of oral and intramuscular S-adenosyl-L-methionine 1,4-butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. Am J Clin Nutr. 2002; 76(5):1172S-6S. DOI: 10.1093/ajcn/76/5.1172S. View

13.

Levkovitz Y, Alpert J, Brintz C, Mischoulon D, Papakostas G . Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder. Eur Psychiatry. 2011; 27(7):518-21. DOI: 10.1016/j.eurpsy.2011.03.006. View

14.

Papakostas G, Shelton R, Zajecka J, Etemad B, Rickels K, Clain A . L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. Am J Psychiatry. 2012; 169(12):1267-74. DOI: 10.1176/appi.ajp.2012.11071114. View

15.

Gabbay V, Freed R, Alonso C, Senger S, Stadterman J, Davison B . A Double-Blind Placebo-Controlled Trial of Omega-3 Fatty Acids as a Monotherapy for Adolescent Depression. J Clin Psychiatry. 2018; 79(4). PMC: 6625364. DOI: 10.4088/JCP.17m11596. View

16.

Sliwinski W, Gawlik-Kotelnicka O . Circulating B vitamins metabolites in depressive disorders - connections with the microbiota-gut-brain axis. Behav Brain Res. 2024; 472:115145. DOI: 10.1016/j.bbr.2024.115145. View

17.

Rosenbaum J, Fava M, Falk W, Pollack M, Cohen L, Cohen B . The antidepressant potential of oral S-adenosyl-l-methionine. Acta Psychiatr Scand. 1990; 81(5):432-6. DOI: 10.1111/j.1600-0447.1990.tb05476.x. View

18.

Panagiotakos D, Mamplekou E, Pitsavos C, Kalogeropoulos N, Kastorini C, Papageorgiou C . Fatty acids intake and depressive symptomatology in a Greek sample: an epidemiological analysis. J Am Coll Nutr. 2011; 29(6):586-94. DOI: 10.1080/07315724.2010.10719897. View

19.

Kelly C, McDonnell A, Johnston T, Mulholland C, Cooper S, McMaster D . The MTHFR C677T polymorphism is associated with depressive episodes in patients from Northern Ireland. J Psychopharmacol. 2004; 18(4):567-71. DOI: 10.1177/0269881104047285. View

20.

Mischoulon D, Dunlop B, Kinkead B, Schettler P, Lamon-Fava S, Rakofsky J . Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation: A Randomized Dose-Finding Clinical Trial. J Clin Psychiatry. 2022; 83(5). DOI: 10.4088/JCP.21m14074. View